Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference

BusinessWire_EN 
0 0 10.11.21
Aurinia Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
 

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation during the 2021 Jefferies London Healthcare Conference -- November 16-19, 2021. The presentation will be available to all conference attendees on demand (link here) beginning on Thursday, November 18 at 8 am GMT/3 am EST through Friday, November 19 at 5 pm GMT/12 pm EST.

Interested parties can also register and access the on-demand webcast through the Investor section of the Aurinia corporate website - www.auriniapharma.com, under "News/Events.”

ABOUT AURINIA

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company recently introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005974/en/

Aurinia Pharmaceuticals Inc. Stock

€4.54
-5.160%
Aurinia Pharmaceuticals Inc. took a tumble today and lost -€0.243 (-5.160%).
The community is currently still undecided about Aurinia Pharmaceuticals Inc. with 0 Buy predictions and 1 Sell predictions.
However, we have a potential of 120.51% for Aurinia Pharmaceuticals Inc. as the target price of 10 € is above the current price of 4.54 €.
Show more
Like: 0
Share
BusinessWire_EN 
Business Wire, a Berkshire Hathaway company, is the global leader in press release distribution and regulatory disclosure. Investor relations, public relations, public policy and marketing professionals rely on Business Wire for secure and accurate distribution of market-moving news and multimedia.

Legal notice

Comments

Not a member yet? Sign up for free!